Intercell AG Information

Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna. It employs 400 people in Austria, Scotland and the United States. It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology. Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production. The most important projects of Intercell are: Vaccine against Japanese encephalitis (approved in Europe, America and Australia) Therapeutic vaccine against hepatitis C (in clinical phase II) Antigen identification program and adjuvant technologies. Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)

Website	http://www.intercell.com
Ticker	VIE:ICLL
Revenue	$23.2 million
Employees	View employees
Founded	1998
Address	6 Biocenter, Vienna, Vienna, AT
Phone	+43 1 20620
Industry	Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Health Care, Medical
Web Rank	20 Million
Competitors	The Janssen Pharmaceutical Companies of Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Moderna Therapeutics, Bavarian Nordic, Novavax, Valneva +39 more (view full list)
SIC	SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 32 Companies, NAICS Code 541711 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies